bluuebunny/crossref_metadata_2025_split huggingface dataset:
Creative marketing strategies in small museums: up close and innovative
Authors: McNichol Theresa 
Published: November 2005

Abstract

Museums are seeing decreasing resources along with increasing competition (such as the entertainment industry's recent foray into the education arena) for their market share (TiLE, Oct 2002). The prevalent perception that nonprofit institutions as a sector are mismanaged also requires museums to become more businesslike in their management and their marketing (Kotler & Kotler, 1998; Andreasen & Kotler, 2002; Salamon, 2003). Although larger museums have more access to human and economic capital, this article demonstrates how the flexibility and agility of smaller institutions positions them well to leverage their resources with creativity and innovation. To give credibility to the museum examples, the discussion recounts how the American wine industry rose in prominence both at home and abroad by sidestepping traditional marketing research methods, using instead an approach that was more like art.

Copyright © 2005 John Wiley & Sons, Ltd.
The marketing/creativity interface: a case study of a visual artist
Authors: O'Reilly Daragh 
Published: November 2005

Abstract

This paper aims to contribute to an understanding of the marketing/creativity interface in the visual arts at the level of the individual artist. Proceeding, broadly speaking, from a constructivist perspective and using a qualitative case study approach, it examines a visual artist's personal construction of her creative and business work. The analysis highlights the significance of emotional, cognitive, spiritual and physical processes for the artist's positioning, process, and products, as well as her difficulties with promotion and pricing issues. It was seen, following Fillis (2004), that, at the level of an individual artist, her work may be not only product‐oriented but self‐oriented. It therefore behoves artists and their agents to be able to offer appropriately distinguishing promotional accounts of the artist's artistic identity, process and work based on a deep self‐reflexive awareness and understanding by the artist of her own creative practice.

Copyright © 2005 John Wiley & Sons, Ltd.
Creativity, job performance and their correlates: a comparison between nonprofit and profit‐driven organizations
Authors: Suh Taewon , Shin Hochang 
Published: November 2005

Abstract

This study explores a research model concerning creativity, job performance, and their correlates in the nonprofit organization setting. The findings of this study suggest that a set of differences in the areas of creativity, job performance, and their correlates exists between the marketers in nonprofit organizations and the marketers in profit‐driven organizations. These findings reveal the need for contingency theories in this area, with emphasis centered on environmental differences. It is hoped that this study will draw the attention of many researchers toward topics concerning organizational creativity in the nonprofit organization setting.

Copyright © 2005 John Wiley & Sons, Ltd.
Effect of immobilization with chondroitin‐6‐sulfate and grafting with chitosan on fibroblast and antibacterial activity of polyester fibers
Authors: Jou Chi‐Hsiung , Lee Jui‐Sheng , Chou Wen‐Li , Yu Da‐Guang , Yang Ming‐Chien 
Published: November 2005

AbstractPoly(ethylene terephthalate) (PET) fibers were treated with 60Co‐γ‐ray and grafted with acrylic acid (AA), and further grafted with chitosan (CS) via esterification. Afterwards these CS‐grafted fibers were then immobilized with chondroitin‐6‐sulfate (ChS). The blood compatibility of PET was reduced by grafting with CS, while improved by immobilizing with ChS. The antibacterial activity of CS against Staphylococcus aureus, and Pseudomonas aeruginosa was retained after ChS‐immobilization. After immobilizing ChS, the L929 fibroblasts cell proliferation was higher than CS‐grafting PET fibers. The results indicate that by grafting with CS and immobilizing with ChS, PET fibers can not only exhibit antibacterial activity, but also improve the cell proliferation for fibroblast activity. Copyright © 2005 John Wiley & Sons, Ltd.
Results of a phase II trial testing interferon‐alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia
Authors: Millot Frédéric , Guilhot Joelle , Nelken Brigitte , Leblanc Thierry , Leverger Guy , Bernard Frédéric , Gandemer Virginie , Béhard Catherine , Berger Claire , Cornu Guy , Duchène Sylvain , Guilhot François 
Published: November 2005

AbstractBackgroundChronic myelogenous leukemia (CML) is a rare disease in children and only few data are available concerning the results of interferon based therapy in this age group. Before the imatinib mesylate era, a prospective phase II trial was conducted to assess the efficacy and tolerance of a combination of interferon‐alpha 2b (IFN) and cytarabine in children with CML in first chronic phase without a suitable HLA‐identical donor.ProcedureFourteen consecutive children were recruited from 12 pediatric centers. Children received daily IFN (5 million U/m2) and subcutaneous cytarabine (20 mg/m2) for 10 days every month.ResultsThe median duration of follow‐up is 13 months (range 2–32 months). Seven children achieved a complete hematologic response after a median time of treatment of 3 months (range 1 week–4 months). Three children were not evaluable for the cytogenetic response. A major cytogenetic response was achieved in seven patients (including complete cytogenetic response in two patient) within 12 months. The median time to major cytogenetic response was 7 months (range 3–12 months). Thirteen patients discontinued the treatment protocol after a median time of 11 months. Probability of progression free survival at 11 months was 83% (95% CI, 61%–100%). Grade 3 and 4 toxicity was observed in eight patients. The most frequently reported drug‐related events were fever, mucositis, neutropenia, and thrombocytopenia.ConclusionsThe combination of IFN and cytarabine provides hematologic and cytogenetic responses in children and adolescents with CML. In the imatinib mesylate era, the role of this combination as second line therapy in children with CML remains to be determined. Pediatr Blood Cancer 2006; 47:555–559. © 2005 Wiley‐Liss, Inc.
Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: An update from the Diamond Blackfan Anemia Registry
Authors: Lipton Jeffrey M. , Atsidaftos Eva , Zyskind Israel , Vlachos Adrianna 
Published: November 2005

AbstractDiamond Blackfan anemia (DBA) is a heterogeneous genetic disorder characterized by red cell aplasia, congenital anomalies, and a predisposition to cancer. Although incompletely understood, the erythroid failure in DBA appears to result from the accelerated apoptosis of affected erythroid progenitors/precursors. One of what appears to be multiple DBA genes, coding for a ribosomal protein RPS 19, has been cloned. Even within multiplex families individuals may vary dramatically as to the degree of anemia, response to treatment and the presence of congenital anomalies. The Diamond Blackfan Anemia Registry (DBAR), a comprehensive database of pediatric and adult patients with DBA who are enrolled after informed consent, was designed to overcome two significant obstacles encountered in the study of a rare disease; the reporting bias inherent in the literature and the lack of an active patient database. To enroll, patients, their families and their physicians complete a detailed questionnaire. A review of medical records and telephone interviews are performed to complete and clarify the information provided. As of May 1, 2005, 420 patients have been enrolled in the DBAR. Epidemiological, clinical, and laboratory data have been collected and analyzed. The DBAR has provided new information on the clinical presentation, outcome and genetics of DBA as well as a better description of congenital malformations and cancer predisposition. This has resulted both in improved clinical care of patients with DBA as well as providing new insights into the pathophysiology of this complex disorder. © 2005 Wiley‐Liss, Inc.
The effectiveness of a peer support camp for siblings of children with cancer
Authors: Sidhu Ranita , Passmore Anne , Baker David 
Published: November 2005

AbstractBackgroundSiblings of children with cancer have higher levels of psychological stress and adaptational difficulties compared to siblings of healthy children and children with other chronic illness. This is the first study to report on the mental health of Australian siblings of children with cancer and examines the effects of a therapeutic peer support camp—Camp Onwards, as an intervention.ProcedureA protocol, designed to reduce levels of distress, improve social competence, and improve knowledge about the impact of cancer and its treatment was developed. Siblings (n = 26) 8–13 years were assessed using standardised self‐report measures pre and post intervention and at −8 weeks follow‐up with: the Behaviour Assessment for Children (BASC) (Reynolds & Kamphaus, 1992), Self Perception Profile for Children (SPP‐C) (Harter, 1985), Sibling Perception Questionnaire (SPQ) (Carpenter & Sahler, 1991).ResultsChange was measured using paired t tests. At pre‐test, 40% of the sample demonstrated increased levels of emotional distress when compared to the normal population. Post intervention, siblings reported lower levels of distress demonstrated by decreased anxiety (P = 0.01) and positive changes in the Self Report of Personality [BASC] (P = 0.00). Improved social competence was noted in the interpersonal domain of the SPQ (P = 0.01) and also greater social acceptance scores on the SPP‐C (P = 0.01). Improved knowledge about the impact of cancer and its treatment was evidenced by significant reductions in the fear of disease domain on the SPQ (P = 0.01).ConclusionsSiblings who attended Camp Onwards demonstrated improved mental health outcomes that were sustained at follow‐up, demonstrating its effectiveness as an intervention strategy in supporting sibling adjustment. Pediatr Blood Cancer 2006; 47:580–588. © 2005 Wiley‐Liss, Inc.
Bone mineral density in children with sickle cell anemia
Authors: Lal Ashutosh , Fung Ellen B. , Pakbaz Zahra , Hackney‐Stephens Ekua , Vichinsky Elliott P. 
Published: November 2005

AbstractPurposeWe evaluated bone mineral density (BMD) and risk factors for poor bone mineralization in children with sickle cell anemia (SCA).Patients and MethodsTwenty‐five children with severe manifestations of SCA (frequent hospitalizations, growth delay, or need for chronic red cell transfusions) were enrolled. Bone density was assessed at lumbar spine and proximal femur with dual‐energy X‐ray absorptiometry (DXA), and Z‐scores were calculated by comparison with age, sex, and ethnicity‐specific reference data.ResultsThe median age of the study population was 12.8 years (10.2–19.8 years). Calcium intake was inadequate in 60%, and serum 25‐hydroxy vitamin D (25‐OHD) level <50 nM in 74% of patients. Median Z‐scores for lumbar spine (−2.3) and proximal femur (−1.7) were markedly reduced, and 64% (95% confidence interval, 43%–82%) of patients had low bone density. Z‐scores were not related to age, growth delay, chronic transfusions, or ferritin level.ConclusionOur results suggest that children with severe manifestations of SCA have low BMD, and possess significant deficits in dietary calcium and circulating vitamin D. Pediatr Blood Cancer © 2005 Wiley‐Liss, Inc.
Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer
Authors: Freeman Burgess B. , Hinds Pamela , Iacono Lisa C. , Razzouk Bassem I. , Burghen Elizabeth , Stewart Clinton F. 
Published: November 2005

AbstractBackgroundEpoetin alfa (EPO, PROCRIT®) pharmacokinetics and pharmacodynamics were evaluated in children with malignant solid tumors receiving chemotherapy.ProcedureChildren initially received IV EPO 600 IU/kg (max dose 40,000 IU) or placebo once weekly for 16 weeks. Dose was increased to 900 IU/kg (max dose 60,000 IU) for patients not achieving a 1 g/dl increase in hemoglobin by study week 3 or 4. Serial PK samples were collected for 24 hr after the first study dose, and after the 10th or 11th dose. Serum EPO concentrations were analyzed using an ELISA assay, and pharmacokinetics were evaluated using compartmental methods.ResultsTwelve children participated; six (median age 15.2 years; range 9.3–18.6 years) were randomized to receive EPO. All children required dosage increases to 900 IU/kg due to no response. The median (range) apparent EPO AUC0–24 and clearance (CL) were 67.1 IU/ml·hr (13.8–102.6) and 0.26 L/hr/m2 (0.19–1.08), respectively. After the 10th or 11th EPO dose in four of these six EPO patients, the median (range) apparent AUC0–24 and CL of EPO was 126.5 IU/ml·hr (107.3–161.1) and 0.21 L/hr/m2 (0.15–0.25), respectively. No significant correlations were observed between pharmacokinetic parameters and pharmacodynamic effects.ConclusionsEPO disposition in our patients was similar to other pediatric patient populations or adults receiving IV EPO. Interesting but insignificant trends were noted in pharmacodynamic effects. Pediatr Blood Cancer 2006; 47:572–579. © 2005 Wiley‐Liss, Inc.
Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors
Authors: Bomgaars Lisa R. , Megason Gail C. , Pullen Jeanette , Langevin Anne‐Marie , Dale Weitman Steve , Hershon Linda , Kuhn John G. , Bernstein Mark , Blaney Susan M. 
Published: November 2005

AbstractPurposeWe performed a Phase I trial of irofulven (MGI 114) to determine the maximum tolerated dose (MTD), the dose‐limiting toxicity (DLT), and the plasma pharmacokinetics of irofulven in children ≤21 years of age with refractory/recurrent malignancies.Experimental DesignThirty‐five patients were entered into the study, of whom 34 were eligible. Patients received Irofulven daily × 5 days every 28 days over 10 min, following pre‐treatment with ondansetron (0.45 mg/kg) and dexamethasone (12 mg/m2). The initial dose of irofulven was 8 mg/m2 daily, with subsequent escalations to 10, 13, and 17 mg/m2. Plasma pharmacokinetic samples were obtained in a subset patients.ResultsThirty‐two patients were assessable for toxicity, and 30 were assessable for response. In heavily pre‐treated patients, dose‐limiting thrombocytopenia was observed in two patients at the 8 mg/m2/day, and in one patient at the 6 mg/m2/day dose level. In less heavily pre‐treated patients, proteinuria and elevated creatinine were dose limiting in two patients at the 17 mg/m2/day dose level. At 13 mg/m2/day, constipation, hyperkalemia with elevated creatinine, and thrombocytopenia was dose limiting in three patients. There were no complete or partial responses. One patient with poorly differentiated carcinoma had stable disease and received 11 courses of therapy. Patients demonstrated a lower systemic exposure and greater clearance than adults treated at similar dose levels.ConclusionThe MTD of irofulven administered daily × 5 every 28 days with concomitant ondansetron and dexamethasone is 6 mg/m2/day in heavily pre‐treated patients and 10 mg/m2/day in less heavily pre‐treated patients. © 2005 Wiley‐Liss, Inc.
Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII
Authors: Michaels Lisa A. , Philipp Claire S. , Eisele Joan , Pappas Heather , Saidi Parvin 
Published: November 2005

AbstractWe report our experience with a small child with severe factor VII deficiency and a history of frequent and spontaneous life‐threatening hemorrhage. The patient has received several years of successful prophylactic treatment with an every 3‐day infusion program in which she receives recombinant activated factor VII (rVIIa) using multiple doses from a single reconstituted vial over a 72‐hr period. Comparison is made to prophylactic treatment in this same patient using plasma‐derived factor VII (PDVII) using a prothrombin complex concentrate (PCC). Pediatr Blood Cancer 2007;49:736–739. © 2005 Wiley‐Liss, Inc.
An analysis of SEER data of increasing risk of secondary malignant neoplasms among long‐term survivors of childhood brain tumors
Authors: Peterson Katia M. , Shao Cheng , McCarter Robert , MacDonald Tobey J. , Byrne Julianne 
Published: November 2005

AbstractBackgroundAdvances made in treatment of a childhood brain cancer have extended the lives of many children and adolescents. Treatment success, however, brings the opportunity to assess late effects; most worrying among these are secondary malignant neoplasms (SMN). Even though the cumulative incidence is quite small, long‐term follow‐up is required because treatment‐induced cancers can occur years after initial treatment.ProcedureThe purpose of this project was to determine what treatments and what host characteristics of children treated for a primary brain cancer are associated with an increase in the risk of a SMN in long‐term survivors. Data were analyzed from 2,056 5‐year survivors, of primary brain cancer in the surveillance, epidemiology, and end results (SEER) database between 1973 and 1998. Thirty‐nine patients developed a SMN. Cox regression models were used to evaluate the independent contribution of a number of risk factors.ResultsThe most important risk factor for developing a SMN in 5‐year survivors was the era in which the primary cancer was treated. Compared to treatment prior to 1979, patients treated between 1979 and 1984 had a 4.7‐fold increase in risk (P = 0.001), while those treated after 1985 had a 6.7‐fold increase in risk. (P = 0.002). Patients treated most recently carry the greatest risk of SMN development even after controlling for radiotherapy. This could be due to the increase in intensive treatment compared to earlier years.ConclusionAlthough the absolute excess risk of SMN remains quite low, continued surveillance is needed to evaluate long‐term effects of new therapies for primary brain tumors. © 2005 Wiley‐Liss, Inc.
Thymic carcinoma in a child with HIV infection
Authors: McDonald Morgan , McLean Thomas , Belhorn Thomas , Smith Scott Victor , Fordham Lynn Ansley , Woods Charles , Blatt Julie 
Published: November 2005

AbstractHIV infection predisposes to cancer during childhood. In addition to the AIDS‐defining non‐Hodgkin lymphoma (NHL) and Kaposi sarcoma, a range of other lymphoid malignancies and solid tumors have been described. We report the first case of an HIV‐positive child with thymic carcinoma in the setting of regressing thymic cysts. The tumor expressed CKIT but failed to respond to imatinab mesylate after a transient response to multiagent chemotherapy. This case extends the spectrum of pediatric malignancy in the setting of HIV and suggests that patients with presumed benign thymic cysts require ongoing surveillance. Pediatr Blood Cancer 2007;49:1004–1007. © 2005 Wiley‐Liss, Inc.
Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low‐dose cyclophosphamide and anti‐thymocyte globulin
Authors: Ayas M. , Al‐Musa A. , Al‐Jefri A. , Al‐Seraihi A. , Al‐Mahr M. , Rifai S. , El‐Solh H. 
Published: November 2005

AbstractBone marrow failure is the major cause of early mortality in patients with dyskeratosis congenita (DC); early trials with conventional conditioning regimens were associated with remarkable chronic morbidity and mortality, and the optimal conditioning regimen for these patients remains undetermined. We report a case of a child afflicted with DC who underwent related full HLA‐matched stem cell transplant (SCT) using a regimen of low dose cyclophosphamide and antithymocyte globulin (ATG). The regimen was well tolerated and associated with no significant short‐term toxicity. Pediatr Blood Cancer 2007;49:103–104. © 2005 Wiley‐Liss, Inc.
Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: Comparison of fracture risk with the General Practice Research Database
Authors: Högler Wolfgang , Wehl Götz , van Staa Tjeerd , Meister Bernhard , Klein‐Franke Andreas , Kropshofer Gabriele 
Published: November 2005

AbstractBackgroundSkeletal complications during or after treatment of acute lymphoblastic leukemia (ALL) have been frequently reported and can cause substantial morbidity, yet their incidence is not well established. The present study assessed the incidence of fractures, osteonecrosis (ON), and bone pain during ALL treatment and compared the fracture incidence with age‐ and sex‐specific reference data from the UK General Practice Research Database (GPRD).ProcedureMedical records of 122 ALL patients diagnosed at our institution from 1992 to 2004 were reviewed for information on fractures, ON, bone pain, and their anatomical location, risk group, phase of antileukemic therapy, and time since diagnosis. Evaluation of skeletal complications was followed up until July 2005 or the patient's death. Thirteen children were excluded as they were transferred to other institutions shortly after diagnosis.ResultsSkeletal complications occurred at a 5‐year incidence of 32.7%. The 5‐year incidence of fractures, ON, and isolated bone pain was 13.5%, 12.1%, and 12.3%, respectively. The relative rate of fractures adjusted for age and sex was 2.03 (95% confidence interval 1.15–3.57) compared to the GPRD, with greatest rates in children <5 years. Thirty ON occurred in 10 patients with a 15 times greater incidence in children >10 years than in those <5 years. Nearly all skeletal complications occurred during maintenance therapy at a median of 14.92 months (range 0.0–53.8) after diagnosis and in weight‐bearing bones.ConclusionsThe doubled fracture rate and the high incidence of skeletal complications during the first years after diagnosis suggest the developing skeleton is very vulnerable in this period. Adolescents develop more ON whereas younger children may be more prone to fractures. Serious “immediate effects” of chemotherapy on bone appear of great concern and should entail preventative studies in this group of patients. Pediatr Blood Cancer 2007;48:21–27. © 2005 Wiley‐Liss, Inc.
Rotation barriers in condensed rings: an extension of Clar's stability rule
Authors: Chuchev Krum , BelBruno Joseph J. 
Published: November 2005

AbstractThe rotation barrier for a substituent OH in systems of condensed benzene rings was studied using density functional theory. The barrier height depends on the position of the hydroxy group and the number of independent benzene rings in the condensed ring system, in agreement with Clar's π‐electron sextet stability model. Investigating OH‐derivatized polycenes with as many as 19 condensed rings showed that increasing the total size of the system does not contribute significantly to the rotation barrier. Copyright © 2005 John Wiley & Sons, Ltd.